A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

被引：0
|
作者：
Anthony W. Tolcher
Leonard J. Appleman
Geoffrey I. Shapiro
Alain C. Mita
Frank Cihon
Arthur Mazzu
Pavur R. Sundaresan
机构：
[1] START (South Texas Accelerated Research Therapeutics),Early Drug Development Center, Department of Medical Oncology
[2] University of Pittsburgh Cancer Institute,Department of Medicine
[3] Dana-Farber Cancer Institute,Clinical Statistics
[4] Brigham and Women’s Hospital,Pharmacodynamics
[5] Harvard Medical School,undefined
[6] Institute for Drug Development,undefined
[7] Cancer Therapy and Research Center,undefined
[8] Bayer Healthcare Pharmaceuticals Inc.,undefined
[9] Bayer Healthcare Pharmaceuticals Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Cardiovascular adverse event (CAE); Left ventricular ejection fraction (LVEF); Hypertension; QT/QTc interval; Sorafenib; Cardiovascular profile;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：751 / 764
页数：13
相关论文
共 50 条
  • [41] A PHASE 1 OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE ALONE OR COMBINED WITH AN AROMATASE INHIBITOR IN WOMEN WITH ADVANCED BREAST CANCER
    Traina, T. A.
    Yardley, D. A.
    Patel, M. R.
    Schwartzberg, L. S.
    Elias, A.
    Gucalp, A.
    Blaney, M. E.
    Gibbons, J.
    Hudis, C. A.
    LoRusso, P.
    ANNALS OF ONCOLOGY, 2014, 25 : 4 - 4
  • [42] Phase 1 open-label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors
    Tamura, Tomohide
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Asahina, Hajime
    Shibata, Takashi
    Goto, Yasushi
    Tanioka, Maki
    Tamura, Yosuke
    Seki, Yoshitaka
    Chiu, Yi-Lin
    Gupta, Neeraj
    Carlson, Dawn
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [43] Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
    Patel, Manish R.
    Falchook, Gerald Steven
    Wang, Judy Sing-Zan
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Motlagh, Pejvack
    Miah, Kowser
    Mugundu, Ganesh M.
    Jones, Suzanne Fields
    Spigel, David R.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors
    Xue, Liqiong
    Tang, Wenbo
    Zhou, Huan
    Liu, Mulin
    Liu, Yuanyuan
    Wang, Jinhua
    Chen, Jianfeng
    Liu, Mingyao
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Preliminary results of an open labelled phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer
    Ahmed, M.
    Barbachano, Y.
    Riddell, A. M.
    Whittaker, S.
    Newbold, K.
    Harrington, K.
    Marais, R.
    Nutting, C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients
    Chu, Q
    Cianfrocca, ME
    Murray, N
    Oslund, M
    Nelson, LM
    Rowinsky, E
    Schwartz, G
    Goldstein, LJ
    Loftiss, JI
    Paul, E
    Koch, KM
    Pandite, L
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S235 - S235
  • [47] Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
    Michael, Michael
    Gibbs, Peter
    Smith, Robert
    Godwood, Alex
    Oliver, Stuart
    Tebbutt, Niall
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (03) : 253 - 261
  • [48] Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
    Naing, Aung
    Mahipal, Amit
    Javle, Milind
    Wang, Judy
    Bauer, Todd M.
    Bajor, David L.
    Elias, Anthony D.
    Shields, Anthony
    Davis, Elizabeth
    Chawla, Sant
    Safran, Howard
    Powderly, John D.
    D'Amato, Gina
    Meyer, Christian F.
    Tang, Xiongwen
    Yao, Sheng
    Keegan, Patricia
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2025, 8 (01) : 71 - 81
  • [49] Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
    Michael Michael
    Peter Gibbs
    Robert Smith
    Alex Godwood
    Stuart Oliver
    Niall Tebbutt
    Investigational New Drugs, 2009, 27 : 253 - 261
  • [50] Preliminary results from an open-label phase IIa trial evaluating the safety and efficacy of EPO906 in patients with advanced breast cancer.
    Toppmeyer, D
    Kaufman, P
    Crump, M
    Sessa, C
    Mackey, J
    Stein, S
    Anderson, J
    Shortall, J
    Rothermel, J
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S134 - S134
12345